Derby Richard, Vorobeychik Yakov, Schneider Byron J, Lee Jeongeun
Former Chief Medical Officer, Spinal Diagnostics and Treatment Center, Daily City, CA, USA.
Former Clinical Associate Professor, Stanford University, USA.
Interv Pain Med. 2021 Nov 29;1(1):100002. doi: 10.1016/j.inpm.2021.100002. eCollection 2022 Mar.
Explore the effectiveness of thoracic medial branch neurotomy (MBN) using combined radiofrequency neurotomy and neurolytic lesioning.
A retrospective cohort of consecutive patients with chronic thoracic axial pain treated in a community setting.
We included all patients who underwent MBN between 2010 and 2016, selected for MBN primarily based on 70% relief following single or dual diagnostic medial branch blocks. Using 18-gauge cannulas, we placed electrodes and made lesions at the suspected location of the thoracic medial branch based on anatomic knowledge at the time; the thermal lesions were supplemented with 50% dextrose to enhance the lesion radius.
We defined success as ≥50% relief of their index thoracic pain not returning to baseline for at least six months. Patients not reached for follow-up were considered failures for worst-case analysis.
Twenty-eight patients underwent an initial MBN between 2010 and 2016: Twenty-five of twenty-eight (89%) patients reported ≥70% pain reduction not returning to baseline for six months or longer. Using a worst-case analysis (WCA), patients reported average pain relief of 73% CI (63%,84%) with a mean duration of relief following the initial MBN of 9.9 months CI (6, 13.5). Seventeen of the initial 28 patients had a total of 31 repeat MBNs, 13/17 (76%) having pain relief reinstated after one or more repeat MBNs with an average duration of relief following a first repeat MBNs of 10.9 months CI (6.6,15.2).
Thoracic MBN combined with a mild neurolytic is a potentially effective treatment for thoracic pain in patients selected with positive diagnostic MBB. There were no complications noted. One can reinstate pain relief with repeated MBN in most patients should their symptoms return.
探讨联合射频神经切断术和神经溶解术进行胸段内侧支神经切断术(MBN)的有效性。
对在社区环境中接受治疗的慢性胸段轴性疼痛连续患者进行回顾性队列研究。
我们纳入了2010年至2016年间接受MBN治疗的所有患者,这些患者主要基于单次或双重诊断性内侧支阻滞术后疼痛缓解70%而被选入接受MBN治疗。我们使用18号套管针,根据当时的解剖学知识,将电极放置在胸段内侧支的可疑位置并进行毁损;热毁损辅以50%葡萄糖以扩大毁损范围。
我们将成功定义为索引胸段疼痛缓解≥50%且至少六个月未恢复至基线水平。未进行随访的患者在最坏情况分析中被视为失败。
28例患者在2010年至2016年间接受了初次MBN:28例患者中有25例(89%)报告疼痛减轻≥70%且六个月或更长时间未恢复至基线水平。采用最坏情况分析(WCA),患者报告平均疼痛缓解率为73%,置信区间为(63%,84%),初次MBN后的平均缓解持续时间为9.9个月,置信区间为(6,13.5)。最初的28例患者中有17例共进行了31次重复MBN,其中13/17(76%)在一次或多次重复MBN后疼痛缓解得以恢复,首次重复MBN后的平均缓解持续时间为10.9个月,置信区间为(6.6,15.2)。
对于诊断性内侧支阻滞阳性的患者,胸段MBN联合轻度神经溶解术是一种潜在有效的胸段疼痛治疗方法。未观察到并发症。如果症状复发,大多数患者可通过重复MBN恢复疼痛缓解。